|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Bellicum Pharmaceuticals, Inc (BLCM) |
|
|
$0.07 0.00 (0.00%) as of 4:30 Mon 3/4
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
6,100,000 |
Market
Cap: |
455.98(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.0745 - $0.56 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing controllable cellular immunotherapies for the treatment of various forms of cancer. Co. is developing chimeric antigen receptors (CAR)-T cell therapies, which are an approach in which a patient's or donor's T cells are genetically modified to carry CARs. By incorporating its switch technologies, Co. is developing product candidates in various areas of cellular immunotherapy including BPX-601, which is designed to treat solid tumors expressing prostate stem cell antigen; and BPX-603, which is designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Smith Alan K. |
EVP, Technical Operations |
|
2018-01-03 |
4 |
D |
$9.79 |
$5,766 |
D/D |
(589) |
2,574 |
|
- |
|
Smith Alan K. |
EVP, Technical Operations |
|
2018-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,563 |
3,163 |
|
- |
|
Musso Alan A |
CFO and Treasurer |
|
2017-12-11 |
4 |
AS |
$9.33 |
$159,667 |
D/D |
(17,117) |
31,585 |
|
- |
|
Musso Alan A |
CFO and Treasurer |
|
2017-11-27 |
4 |
S |
$9.89 |
$61,382 |
D/D |
(6,206) |
48,702 |
|
- |
|
Naeve Gregory S. |
Sr. VP, Chief Business Officer |
|
2017-08-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
Smith Alan K. |
EVP, Technical Operations |
|
2017-07-24 |
4 |
AS |
$11.85 |
$5,178 |
D/D |
(437) |
1,600 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2017-07-13 |
4 |
AS |
$12.26 |
$169,470 |
D/D |
(13,823) |
491 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2017-07-13 |
4 |
OE |
$2.55 |
$35,249 |
D/D |
13,823 |
14,314 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2017-07-10 |
4 |
AS |
$11.54 |
$115,400 |
D/D |
(10,000) |
138,965 |
|
- |
|
Musso Alan A |
CFO and Treasurer |
|
2017-05-25 |
4 |
S |
$12.24 |
$77,254 |
D/D |
(6,311) |
54,908 |
|
- |
|
Smith Alan K. |
EVP, Technical OprationsOffice |
|
2017-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
874 |
|
- |
|
Baker Bros. Advisors (gp) Llc |
10% Owner |
|
2017-03-24 |
4 |
B |
$12.00 |
$1,999,992 |
I/I |
166,666 |
4,527,089 |
1.5 |
- |
|
Slawin Kevin M. |
Director |
|
2017-02-07 |
4 |
AS |
$12.54 |
$376,215 |
I/I |
(30,000) |
294,982 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-12-15 |
4 |
AS |
$15.45 |
$463,539 |
I/I |
(30,000) |
324,982 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2016-12-05 |
4 |
AS |
$20.00 |
$100,000 |
D/D |
(5,000) |
146,082 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2016-12-01 |
4 |
AS |
$17.17 |
$87,624 |
D/D |
(5,000) |
151,082 |
|
- |
|
Moseley Annemarie |
COO/EVP Clinical Development |
|
2016-12-01 |
4 |
AS |
$17.17 |
$438,505 |
D/D |
(25,000) |
442 |
|
- |
|
Moseley Annemarie |
COO/EVP Clinical Development |
|
2016-12-01 |
4 |
OE |
$2.55 |
$63,750 |
D/D |
25,000 |
25,442 |
|
- |
|
Musso Alan A |
CFO and Treasurer |
|
2016-11-28 |
4 |
AS |
$19.23 |
$443,160 |
D/D |
(23,027) |
60,548 |
|
- |
|
Musso Alan A |
CFO and Treasurer |
|
2016-11-25 |
4 |
AS |
$20.48 |
$128,480 |
D/D |
(6,273) |
83,575 |
|
- |
|
Spencer David M. |
Chief Scientific Officer |
|
2016-09-23 |
4 |
AS |
$20.19 |
$125,172 |
D/D |
(6,200) |
156,082 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-23 |
4 |
AS |
$20.10 |
$235,198 |
D/D |
(11,700) |
344 |
|
- |
|
Moseley Ken |
Sr. VP and General Counsel |
|
2016-09-23 |
4 |
OE |
$7.47 |
$87,399 |
D/D |
11,700 |
12,044 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-23 |
4 |
AS |
$20.11 |
$240,530 |
I/I |
(11,958) |
354,982 |
|
- |
|
Slawin Kevin M. |
Chief Technology Officer |
|
2016-09-23 |
4 |
AS |
$20.12 |
$226,549 |
D/D |
(11,258) |
84,206 |
|
- |
|
179 Records found
|
|
Page 4 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|